Doctors track Real-World safety of approved stomach cancer drug
NCT ID NCT06902545
Summary
This study is collecting information on the safety and effectiveness of VYLOY (zolbetuximab), an already approved drug, for people in South Korea with advanced stomach or gastroesophageal junction cancer. About 377 participants receiving the drug as part of their standard care will be observed for about a year. The main goal is to understand the real-world side effects and how long the cancer stays stable after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA OR CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
KR82001
RECRUITINGSeoul, South Korea
-
KR82002
RECRUITINGSeoul, South Korea
-
KR82003
RECRUITINGSeoul, South Korea
-
KR82004
RECRUITINGSeoul, South Korea
-
KR82005
RECRUITINGSeoul, South Korea
-
KR82006
RECRUITINGYangsan, Gyeongsangnam-do, South Korea
-
KR82007
RECRUITINGSeoul, South Korea
-
KR82008
RECRUITINGSuwon, Gyeonggi-do, South Korea
-
KR82009
RECRUITINGSuwon, Gyeonggi-do, South Korea
-
KR82010
RECRUITINGGoyang-si, Gyeonggi-do, South Korea
-
KR82011
RECRUITINGSeoul, South Korea
-
KR82012
RECRUITINGHwasun Gun, Jeollanam-do, South Korea
-
KR82013
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.